Lurbinectedin is a chemotherapy drug used to treat certain types of cancer. It works by preventing cancer cells from dividing and growing [2]. According to the sources provided, there is no information available on whether lurbinectedin can cross the placenta.

The prescribing information for lurbinectedin does not mention anything about its ability to cross the placenta or its effects on a developing fetus [1]. However, it is important to note that chemotherapy drugs are generally not recommended during pregnancy, as they can harm the developing fetus [3].

The Australian Therapeutic Goods Administration (TGA) rates lurbinectedin as a Category D drug, which means that there is evidence of fetal risk, but the benefits of using the drug may outweigh the risks in certain situations [3]. The TGA recommends that lurbinectedin should not be used during pregnancy unless the potential benefits outweigh the risks to the fetus [3].

In conclusion, there is no information available on whether lurbinectedin can cross the placenta. However, chemotherapy drugs are generally not recommended during pregnancy due to the potential harm they can cause to the developing fetus. If lurbinectedin is deemed necessary during pregnancy, the potential benefits and risks should be carefully considered and discussed with a healthcare provider [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/publications/dictionaries/cancer-drug
[3] https://www.tga.gov.au/products/medicines/find-information-about-medicine/prescribing-medicines-pregnancy-database